MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positiv… Read more
MAIA Biotechnology Inc. (MAIA) - Total Assets
Latest total assets as of September 2025: $11.78 Million USD
Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) holds total assets worth $11.78 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MAIA Biotechnology Inc. - Total Assets Trend (2019–2024)
This chart illustrates how MAIA Biotechnology Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
MAIA Biotechnology Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
MAIA Biotechnology Inc.'s total assets of $11.78 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.5% |
| Accounts Receivable | $77.35K | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how MAIA Biotechnology Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MAIA Biotechnology Inc.'s current assets represent 100.0% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 94.5% of total assets in 2024, down from 98.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
MAIA Biotechnology Inc. Competitors by Total Assets
Key competitors of MAIA Biotechnology Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
MAIA Biotechnology Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - MAIA Biotechnology Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - MAIA Biotechnology Inc. is currently not profitable relative to its asset base.
MAIA Biotechnology Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.18 | 2.56 | 0.44 |
| Quick Ratio | 1.18 | 2.56 | 0.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.76 Million | $ 5.63 Million | $ -947.24K |
MAIA Biotechnology Inc. - Advanced Valuation Insights
This section examines the relationship between MAIA Biotechnology Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1706.31 |
| Latest Market Cap to Assets Ratio | 4.75 |
| Asset Growth Rate (YoY) | 34.2% |
| Total Assets | $10.16 Million |
| Market Capitalization | $48.22 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values MAIA Biotechnology Inc.'s assets at a significant premium ( 4.75x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: MAIA Biotechnology Inc.'s assets grew by 34.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MAIA Biotechnology Inc. (2019–2024)
The table below shows the annual total assets of MAIA Biotechnology Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $10.16 Million | +34.21% |
| 2023-12-31 | $7.57 Million | -37.06% |
| 2022-12-31 | $12.02 Million | +6.13% |
| 2021-12-31 | $11.33 Million | +1417.36% |
| 2020-12-31 | $746.50K | -56.96% |
| 2019-12-31 | $1.73 Million | -- |